BSTC BioSpecifics Technologies Corp

48.78
-0.56  -1%
Previous Close 49.34
Open 49.08
Price To Book 3.24
Market Cap 357,574,424
Shares 7,330,349
Volume 56,150
Short Ratio
Av. Daily Volume 46,907
Stock charts supplied by TradingView

NewsSee all news

  1. BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

    LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
BLA filing announced September 6, 2019.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 new data to be presented 2H 2019.
XIAFLEX
Uterine fibroids

Latest News

  1. BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

    LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class